Kairos Ventures

TULU is a consumer services company based in Tel Aviv, Israel, that specializes in on-demand rentals of household and lifestyle products. Founded in 2018 by Yishai Lehavi and Yael Shemer, TULU's platform aims to promote responsible consumption and energy efficiency while reducing urban living costs. The company offers a diverse range of products, including brand-name appliances, grocery staples, micromobility devices, and entertainment equipment, all accessible through its application. By utilizing IoT-based technology, TULU optimizes space and product usage, helping urban dwellers minimize waste and enhance their overall living experience.

Vivodyne specializes in developing an automated robotic platform that aims to advance drug discovery and cellular therapies. The company's innovative microfluidic bioengineering technology facilitates the culture of highly realistic human tissue models, allowing researchers to explore complex biological processes. By employing single-cell 4D phenomics and integrating advanced imaging techniques, Vivodyne's system enables the formulation of tailored mixtures of compounds and cell therapies. This comprehensive approach not only accelerates the development of potential cures for various human diseases but also enhances the understanding of human health at a cellular level.

Developer of acoustic wave technology designed to control electronic devices without the need to touch the screen. The company's technology uses signal processing algorithms that take advantage of unique aspects of the acoustic signals to provide accurate 2D tracking to control a smartphone, tablet, computer, and even some larger consumer electronics, enabling application developers to minimize suffering from severe power usage or privacy issues that occur when using a typical camera-based technology.

Novosteo Inc. is a company founded in 2017 and located in West Lafayette, Indiana, that focuses on developing and manufacturing innovative drugs aimed at healing bone fractures. The company utilizes a specialized drug discovery platform designed to target the specific needs of fracture healing. By concentrating the healing properties of its drugs at the site of the fracture, Novosteo aims to accelerate the recovery process and enhance the overall healing experience for patients. This approach seeks to mitigate the morbidity, mortality, and productivity loss associated with bone fractures, ultimately improving patient outcomes and reducing the debilitating effects that can arise from such injuries.

Provivi Inc. develops biopesticides for agriculture, commercial, household, and public health pest management. It develops research quantities of carbene/nitrene transferase enzymes that activate diazo and azide compounds to generate iron-carbenoids and iron-nitrenoids through a mode of activation. The company also develops a biocatalysis and fermentation technology, which is based on biocatalysts that enable efficient synthesis of biopesticides. Its technology has applications in industries, such as pharmaceuticals, nutrition, flavors, and fragrances. The company offers its products through distributors worldwide. Provivi Inc. was incorporated in 2012 and is based in Santa Monica, California.

Foldax, Inc. is a company based in Salt Lake City, Utah, specializing in the design and manufacture of heart valves for individuals suffering from aortic, mitral, or tricuspid valve disease. Founded in 2013, Foldax focuses on developing synthetic heart valves that aim to be non-thrombogenic, providing a cost-effective alternative to existing artificial or tissue valves. The company offers its Tria biopolymer heart valves, which can be implanted either percutaneously or surgically, thereby addressing critical needs in cardiac care.

Turbodega S.A.C. is a technology company based in Peru that offers a mobile application platform designed for retailers and distributors, particularly small grocery stores. Founded in 2018, the company focuses on digitizing and optimizing inventory and supply chains through the use of artificial intelligence. Its software management tool enables bodegas to automate their ordering processes, optimize inventory levels, and track daily sales in real-time. By integrating the entire supply chain into a digital ecosystem, Turbodega enhances operational efficiency and provides valuable insights to its users, facilitating better decision-making in inventory management.

PteroDynamics specializes in the development of a patented aircraft design known as Transwing, which features wings that fold and unfold during flight. This innovative design enables the aircraft to transition seamlessly between a multicopter and a fixed-wing airplane, resulting in enhanced efficiency and performance. PteroDynamics' aircraft are smaller, safer, and capable of carrying heavier payloads while consuming less energy than traditional vertical takeoff and landing (VTOL) aircraft. This technology is particularly advantageous for applications in drone delivery, air taxis, and various government and military operations, as it allows for longer flight ranges and faster travel times.

Actinia develops a technology designed to detect hard radiation such as gamma rays and X-rays. Its company's perovskite-based material exhibit higher X-ray sensitivity and better gamma-ray energy resolution, enabling its clientele with detector technologies across the nuclear energy, non-proliferation, and medical imaging sectors.

Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy, a key cell survival and treatment resistance pathway in cancer. Pinpoint inhibitors target a recently discovered enzyme in the autophagy pathway called PPT1, which is highly expressed across most cancers. These inhibitors could be applied to a broad range of cancers alone or in combination to overcome therapy resistance.

Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics that target Glycogen Synthase Kinase-3ß (GSK-3ß) for Alzheimer’s disease, bipolar disorder, diabetes mellitus type II, inflammatory conditions, and cancer. It develops compounds for combination use in high impact carcinomas, including glioblastoma, ovarian, breast, and pancreatic cancers. Actuate Therapeutics, Inc. was formerly known as Apotheca Therapeutics, Inc. The company was incorporated in 2015 and is based in Fort Worth, Texas with an additional office in Dublin, Ireland.

GuRu Wireless, Inc. makes wireless power products that just work – no training required. The company uses millimeter-wave (mmWave) technology to deliver electric power through the air nearly as fast as over wires to multiple devices simultaneously. GuRu’s products are safe, easy to use, and intelligent – automatically finding and adjusting power levels for any device. Founded by a team of Caltech electrical engineers, applied physicists, and integrated circuit and phased array experts, GuRu is based in Pasadena, Calif.

MixComm Inc. is a fabless semiconductor company based in Chatham, New Jersey, established in 2017. The company specializes in developing wireless technology solutions for a variety of applications, including smartphones, laptop computers, Wi-Fi routers, smart TVs, game consoles, virtual-reality headsets, and radar systems used in vehicles and defense electronics. By focusing on innovative wireless communications technologies, MixComm aims to enhance connectivity and performance across different electronic devices.

Provivi Inc. develops biopesticides for agriculture, commercial, household, and public health pest management. It develops research quantities of carbene/nitrene transferase enzymes that activate diazo and azide compounds to generate iron-carbenoids and iron-nitrenoids through a mode of activation. The company also develops a biocatalysis and fermentation technology, which is based on biocatalysts that enable efficient synthesis of biopesticides. Its technology has applications in industries, such as pharmaceuticals, nutrition, flavors, and fragrances. The company offers its products through distributors worldwide. Provivi Inc. was incorporated in 2012 and is based in Santa Monica, California.

Linnaeus Therapeutics, Inc. is a biotechnology company focused on identifying and developing small molecule agents for the treatment of cancer and disorders of pigmentation. Founded in 2016 and based in Haddonfield, New Jersey, the company leverages discoveries from the Ridky lab at the University of Pennsylvania. As a development stage biotech firm, Linnaeus Therapeutics aims to modulate cellular differentiation to advance therapeutic options in oncology.

New Age Meats is a biotechnology company based in San Francisco, California, founded in 2017. The company specializes in producing cultivated meat using an automated, data-driven platform and advanced stem cell technology. By growing meat from animal cells rather than relying on traditional animal slaughter, New Age Meats aims to create healthier and more sustainable meat alternatives.

Kencko Foods, Inc. specializes in producing and selling organic fruit and vegetable products across the United States, the United Kingdom, and Canada. Founded in 2017 and headquartered in New York, the company operates a processing facility in Lisbon, Portugal. Kencko focuses on reinventing fresh organic produce into convenient, hassle-free products, including sachet-based instant smoothies that come in various pack sizes. These smoothies contain no added sugar, chemicals, or colorants, preserving the nutritional content of the ingredients. Kencko aims to make it easy for consumers to incorporate healthy and tasty organic fruits and vegetables into their daily routines.

Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics that target Glycogen Synthase Kinase-3ß (GSK-3ß) for Alzheimer’s disease, bipolar disorder, diabetes mellitus type II, inflammatory conditions, and cancer. It develops compounds for combination use in high impact carcinomas, including glioblastoma, ovarian, breast, and pancreatic cancers. Actuate Therapeutics, Inc. was formerly known as Apotheca Therapeutics, Inc. The company was incorporated in 2015 and is based in Fort Worth, Texas with an additional office in Dublin, Ireland.

Xidas Inc. specializes in designing, developing, and manufacturing advanced microscopic electronic products for various sectors, including industrial, life-tech, and the Internet of Things (IoT). Established in 2015 and based in Irvine, California, the company employs a unique miniaturization paradigm known as Amalga, which integrates innovative manufacturing technologies and materials processing. Xidas produces a range of cutting-edge products such as microwave micro relays, micro force sensors, and zero-power implantable sensors, catering to applications in robotics, telecommunications, aerospace, defense, and healthcare. The company focuses on delivering industry-first technologies and highly integrated smart modules, positioning itself to meet the evolving needs of its industrial clients in diverse applications from medical implants to agriculture.

Transient Plasma Systems, Inc. specializes in the development and manufacture of pulsed power systems for various research and commercial applications. Founded in 2009 and based in Torrance, California, the company produces pulse generators and nanosecond pulsed power systems that facilitate voltage and current measurement. Its innovative technology utilizes ultra-fast, high-voltage electrical pulses to create energetic electrons throughout a volume, rather than focusing them at a single point, which results in a more efficient ignition process. This technology has significant applications across multiple sectors, including combustion, pollution treatment, medical, bio-electrics, automotive, defense, aerospace, heavy transport, energy, and agriculture. By enabling longer spark plug life and enhancing combustion efficiency, Transient Plasma Systems aims to drive technological advancements and improve operational effectiveness in these industries.

Stoicheia is a nanotechnology company accelerating materials discovery by defining and expanding the materials genome. Using its proprietary lithography technology, Stoicheia has developed a way to create Megalibraries of nanomaterials on a chip. The company's technology also can be used to combine elements in new ways — already creating structures comprising up to seven elements.

Siege Pharmaceuticals develops cancer drugs based on a naturally occurring molecule that starves cancer cells to death. Its synthetic variants with optimized drug-like properties are based on a naturally occurring molecule and target multiple pathways that cancer cells need for growth, thereby enabling medical practitioners to control the growth and resistance of cancer cells from developing further.

NVasc is an early-stage ophthalmology company with a focus on treating blindness. It specializes in treating the leading causes of blindness through choroidal and retinal revascularization. The company has acquired the research rights to growth factors (NVB001 and NVB002) that have been shown to encourage the growth of non-leaking new vessels in the retina and choroid in mouse models of ischemic eye diseases. The company is planning to manufacture NVB001 which can be used in toxicokinetic studies and in early clinical trials in humans.

Linnaeus Therapeutics, Inc. is a biotechnology company focused on identifying and developing small molecule agents for the treatment of cancer and disorders of pigmentation. Founded in 2016 and based in Haddonfield, New Jersey, the company leverages discoveries from the Ridky lab at the University of Pennsylvania. As a development stage biotech firm, Linnaeus Therapeutics aims to modulate cellular differentiation to advance therapeutic options in oncology.

LifeSprout is developing the next generation of synthetic soft tissue substitutes for aesthetic and reconstructive medicine. LifeSprout offers revolutionary products for aesthetic and regenerative medicine. Leveraging recent breakthroughs in materials science, we have created a platform that looks and behaves like the body’s own tissues. The company is turning this into a suite of products for millions of patients each year with soft tissue losses from aging, cancer, and metabolic disease.

PolyCera, Inc. develops and manufactures PolyCera membranes made up of organic polymer materials used for ultrafiltration (UF) offering a combination of hydrophilicity, permeability, and robustness. Its products include PolyCera hydro, a sub-20 nm UF membrane that delivers removal of bacteria, virus, and protozoa; and PolyCera titan, a sub-5 nm pore size UF membrane that delivers oil, hydrocarbon, pH, and temperature stability. The company was founded in 2012 and is based in Los Angeles, California.

nFugue is building on the groundbreaking work developed at Caltech to open a new level of nano-architected materials that can be used for a wide variety of applications, from tiny medical implants to ultra-lightweight impact-resistant fabrics or textiles to ultra-lightweight aircraft components. The revolutionary process will reduce the size of the 3D printed structures by 5x while enabling a whole new set of unprecedented combinations of properties, for example, ultra-lightweight; thermally insulating; strong, stiff, and low-density; and impact-absorbing.

Tanvas, Inc. engages in the development of Surface Haptics technology-based products. The company develops touch screen technology which uses electrostatic fields to create computer-controlled variable friction on the glass and enables people to feel what they see on a screen. Tanvas, Inc. was formerly known as Tangible Haptics LLC. The company was incorporated in 2011 and is based in Chicago. Illinois.

Keren Therapeutics is harnessing the biology of a naturally occurring peptide hormone to restore muscle function in the context of several musculoskeletal and muscle wasting diseases. Using the same biological insights, Keren is also developing a therapeutic to counteract cognitive decline associated with age-related neurodegenerative conditions.

Provivi Inc. develops biopesticides for agriculture, commercial, household, and public health pest management. It develops research quantities of carbene/nitrene transferase enzymes that activate diazo and azide compounds to generate iron-carbenoids and iron-nitrenoids through a mode of activation. The company also develops a biocatalysis and fermentation technology, which is based on biocatalysts that enable efficient synthesis of biopesticides. Its technology has applications in industries, such as pharmaceuticals, nutrition, flavors, and fragrances. The company offers its products through distributors worldwide. Provivi Inc. was incorporated in 2012 and is based in Santa Monica, California.

1200 Pharma uses breakthrough medicinal chemistry technology from Caltech and proprietary biomarker-driven assays from UCLA to dramatically accelerate pre-clinical drug discovery and clinical approval timelines.

Symbiotix Biotherapies specializes in developing a novel class of molecular therapeutics aimed at treating inflammatory bowel disease, multiple sclerosis, and other serious immune-mediated conditions. The company's innovative oral agents are derived from molecules sourced from the human microbiome, providing patients with first-in-class therapies that enhance their quality of life and empower them to manage their health more effectively. By focusing on Treg-modulating therapeutics, Symbiotix Biotherapies is positioned to make significant advancements in the treatment of various immune-related disorders.

MixComm Inc. is a fabless semiconductor company based in Chatham, New Jersey, established in 2017. The company specializes in developing wireless technology solutions for a variety of applications, including smartphones, laptop computers, Wi-Fi routers, smart TVs, game consoles, virtual-reality headsets, and radar systems used in vehicles and defense electronics. By focusing on innovative wireless communications technologies, MixComm aims to enhance connectivity and performance across different electronic devices.

Diabetic Retinopathy is the leading cause of vision loss in adults worldwide. Opera Therapeutics is developing treatments based on technology from Columbia University that harnesses a natural cellular mechanism to prevent the damage and cell death that are hallmarks of Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO) which account for the majority of vision loss amongst people with diabetes. Unlike currently available anti-angiogenesis therapies which are injected directly into the eye, carry the risk of thromboembolic side effects, and are frequently ineffective, Opera Therapeutics is developing a biologic with a unique mechanism of acting for topical administration as an eye-drop, and aims to bring enhanced relief to patients suffering from diabetic retinopathy without the requirement for regular interocular injections. Opera Therapeutics is additionally exploring the utility of their biologics for treating stroke-induced edema in the brain.

Sienza Energy is developing a radical new approach to design and manufacture batteries. The company’s revolutionary strategy is based on a 3D nanotechnology electrode structure that takes advantage of advances in multiple fields over the last decade, providing an approach to battery design that is unique in the industry. By combining these advances in an innovative way, Sienza can drastically improve the batteries’ energy and power densities — all with the goal of simultaneously reducing the overall battery costs. With this new approach, Sienza Energy can provide even more capability in a range of products, from smart devices to electric vehicles.

Repairogen is developing premium anti-aging skincare ingredients and products based on a platform technology invented at an ivy-league medical research institution. Products incorporating its proprietary and scientifically proven technology will provide customers with healthier and younger-looking skin. It was founded in 2012 and headquartered in New York, United States.

GuRu Wireless, Inc. makes wireless power products that just work – no training required. The company uses millimeter-wave (mmWave) technology to deliver electric power through the air nearly as fast as over wires to multiple devices simultaneously. GuRu’s products are safe, easy to use, and intelligent – automatically finding and adjusting power levels for any device. Founded by a team of Caltech electrical engineers, applied physicists, and integrated circuit and phased array experts, GuRu is based in Pasadena, Calif.

Transient Plasma Systems, Inc. specializes in the development and manufacture of pulsed power systems for various research and commercial applications. Founded in 2009 and based in Torrance, California, the company produces pulse generators and nanosecond pulsed power systems that facilitate voltage and current measurement. Its innovative technology utilizes ultra-fast, high-voltage electrical pulses to create energetic electrons throughout a volume, rather than focusing them at a single point, which results in a more efficient ignition process. This technology has significant applications across multiple sectors, including combustion, pollution treatment, medical, bio-electrics, automotive, defense, aerospace, heavy transport, energy, and agriculture. By enabling longer spark plug life and enhancing combustion efficiency, Transient Plasma Systems aims to drive technological advancements and improve operational effectiveness in these industries.

They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia and lymphoma, have shown transformative results for patients unresponsive to standard therapy. However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients. Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w

NanoClear Technologies is a fast-paced, institutional venture capital-backed startup in the nanotechnology and energy space. Headquartered in Los Angeles, NanoClear utilizes technologies developed by our co-founder while working at JPL/NASA as well as the contributions from our other staff who include alumni from Caltech, UC Berkeley, UCLA, and MIT. NanoClear Technologies has a proprietary process that can alter wettability of any arbitrary surface. The primary application of the technology is to provide anti-fogging capabilities in consumer wearables and anti-frost performance in a variety of industrial applications. Furthermore, NanoClear's technology platform can be applied to a variety of industries and devices including automobile, consumer wearables, aerospace, and solar panels.

DEARhealth, Inc. is a health technology company based in Beverly Hills, California, that specializes in developing a software-as-a-service (SaaS) healthcare management platform tailored for medical providers and health insurers. Founded in 2013, the company focuses on value-based healthcare solutions aimed at enhancing the health outcomes and experiences of chronically ill patients while simultaneously reducing associated costs. Utilizing advanced data analytics, DEARhealth's platform facilitates coordinated care pathways, streamlines provider workflows, and supports organizational decision-making. The technology is specifically designed for the management of complex and costly diseases, enabling healthcare professionals to optimize care and improve measurable patient outcomes.

Actinobac Biomed, Inc. is a biopharmaceutical company based in Kendall Park, New Jersey, established in 2009. The company focuses on developing therapeutics for various medical conditions, including blood cancers, autoimmune diseases, and HIV. Its primary product, Leukotoxin, is a bacterial toxin that specifically targets white blood cells, offering a targeted approach for treating hematologic malignancies such as leukemia and lymphoma. Additionally, research indicates that Leukotoxin may be effective against infectious diseases like HIV/AIDS and tuberculosis, as well as autoimmune conditions including rheumatoid arthritis, multiple sclerosis, and psoriasis. Actinobac Biomed is committed to advancing Leukotoxin as a protein therapeutic, while also exploring derived peptides for broader applications. The company is engaged in early-stage drug discovery in collaboration with Magellan BioScience, aiming to maintain a robust pipeline of innovative therapeutic agents.

3D Bio Holdings is a biotechnology company specializing in bioprinting technologies to create patient-specific living tissues for surgical healing. Founded in 2014, the company is headquartered in Brooklyn, New York, with an additional office in New York City. Utilizing proprietary technologies such as GMPrint and ColVivo, 3D Bio Holdings aims to address the limitations of the body's natural healing processes by providing therapeutic solutions for various diseases and congenital medical conditions.

Holoclara is a immunotherapy company that offers autoimmune disorders with nematode derived molecules.

Neuro-Bio is a start-up company focused on the development of novel, effective therapeutics for neurodegenerative disorders such as Alzheimer’s, Parkinson’s and Motor Neuron Disease. The Company’s uniqueness lies in its innovative identification of the initial trigger of neurodegeneration - this has been developed throughout Baroness Professor Susan Greenfield’s highly credited 40 year career in neuroscience.

Amorphology uses metal alloy technologies and production techniques to create specialty gears for non-commercial robotics applications.

Behavioral Signals (Behavioral Signal Technologies, Inc.) develops technology to analyze human behavior from voice-data. Using the Oliver API for Emotions & Behavior Recognition, our flagship product, enterprises can track emotions and behaviors in conversations and get a complete view of related key performance indicators. Our award-winning emotion recognition and behavioral prediction analytics technology utilizes cognitive modeling and advanced machine learning algorithms. This enables us to provide enriched conversational insights for interaction with voice assistants, chatbots, robotic virtual assistants, social healthcare robotics and mobile voice assistants. We understand not only what is being said but how it is being said, the emotions, intentions, state-of-mind and behaviors of each person. We leverage huge amounts of voice-data and deep learning to provide valuable data-informed business insights, while technically enabling human-to-machine conversational AI to have meaningful interactions, making the experience feel like chatting with a friend or someone who really understands you and responds appropriately.

Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. The company leverages its microbiome discovery platform to explore the gut-brain axis, which presents opportunities for creating innovative therapies aimed at enhancing the quality of life for individuals affected by neurological conditions. Founded in 2013 and based in Waltham, Massachusetts, Axial Therapeutics aims to address significant unmet medical needs within the CNS therapeutic landscape.

Axial Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. The company leverages its microbiome discovery platform to explore the gut-brain axis, which presents opportunities for creating innovative therapies aimed at enhancing the quality of life for individuals affected by neurological conditions. Founded in 2013 and based in Waltham, Massachusetts, Axial Therapeutics aims to address significant unmet medical needs within the CNS therapeutic landscape.

Gene Sciences, Inc. is a biotechnology company based in San Diego, California, established in 2016. The company focuses on developing innovative DNA-targeted therapeutics aimed at modulating gene expression for the treatment of various human diseases. Serving customers primarily in the United States, Gene Sciences is dedicated to advancing healthcare solutions through its research and development efforts in the biopharmaceutical sector.

MemiRay, LLC, founded in 2016 and based in Arcadia, California, specializes in the development of personal health monitoring devices. The company's flagship product, InstaPath, is designed to measure multiple human fluid analytics simultaneously, targeting conditions such as Diabetes Mellitus and Coronary Heart Disease while also monitoring hydration levels. In addition to its hardware, MemiRay offers cloud-based informatics software that ensures data integrity, security, and precise time stamping, facilitating effective record keeping and methodology management. The company's products are aimed at a wide range of users, including individuals and various healthcare facilities such as hospitals, surgery centers, and pathology labs. MemiRay's innovative approach emphasizes convenience, portability, and ease of use, contributing to improved health outcomes and reduced overall healthcare costs.

Applaud Medical, Inc. is a medical device company based in San Francisco, California, focused on developing and commercializing innovative treatments for kidney stones, a condition affecting over 2 million individuals annually in the United States. Established in 2014, the company aims to address the limitations of current treatment options, which often require anesthesia and operating room procedures for large stones. The existing least invasive surgical interventions achieve only a 50% stone-free rate. Applaud Medical's breakthrough approach will enable urologists to effectively treat 5-15 millimeter kidney stones through a simple outpatient procedure, significantly improving patient outcomes and convenience.

Compellon, Inc. is a data analytics software company based in Laguna Hills, California, founded in 2010. It specializes in providing prescriptive analytics solutions to various industries, including healthcare, financial services, and advertising. Compellon’s flagship products include Iris Pro, an analytics advisory tool; Compellon 20|20, a clear-box analytics platform; and 20|20 Survey, which focuses on survey analytics. The company leverages advanced artificial intelligence techniques to deliver actionable insights rapidly, enabling businesses to make informed decisions without requiring extensive technical expertise. By automating the analytics process, Compellon empowers organizations to optimize outcomes and address complex data challenges efficiently. Its technology functions as an autonomous intelligent agent that tailors analytics based on user-defined goals, allowing both data scientists and business analysts to uncover valuable insights from diverse data sets.

Delpor, Inc. develops innovative drug delivery technologies that facilitate the sustained or pattern-specific release of proteins, peptides, and small molecules through a small non-mechanical subcutaneous implant device. Its key technologies include Prozor, designed for delivering antipsychotics and other small molecule drugs; NANOPOR, which provides sustained release through specialized membrane architecture; and Delos PUMP, a self-contained device that enables drug delivery in predetermined patterns, particularly beneficial for medications requiring pulsed administration, such as fertility hormones and pain medications. Established in 2009, Delpor is headquartered in San Francisco, California.

Provivi Inc. develops biopesticides for agriculture, commercial, household, and public health pest management. It develops research quantities of carbene/nitrene transferase enzymes that activate diazo and azide compounds to generate iron-carbenoids and iron-nitrenoids through a mode of activation. The company also develops a biocatalysis and fermentation technology, which is based on biocatalysts that enable efficient synthesis of biopesticides. Its technology has applications in industries, such as pharmaceuticals, nutrition, flavors, and fragrances. The company offers its products through distributors worldwide. Provivi Inc. was incorporated in 2012 and is based in Santa Monica, California.

Foldax, Inc. is a company based in Salt Lake City, Utah, specializing in the design and manufacture of heart valves for individuals suffering from aortic, mitral, or tricuspid valve disease. Founded in 2013, Foldax focuses on developing synthetic heart valves that aim to be non-thrombogenic, providing a cost-effective alternative to existing artificial or tissue valves. The company offers its Tria biopolymer heart valves, which can be implanted either percutaneously or surgically, thereby addressing critical needs in cardiac care.